Class action noise is a dark cloud, but check this out: the stock is trying to rally *through* it. RSI is deeply oversold (finally!), and the 9-period EMA is trying to claw back above the 21. Volume's decent on the up days. Feels like the bad news is priced in and the tape is sniffing a turnaround. It's a gutsy contrarian BUY. #OversoldBounce 🎢

Law firms are circling like vultures after that 26% plunge. 🚨 But check this: the stock just bounced off its lows with a huge volume spike. RSI is neutral, so the selling pressure might be exhausted. This feels like a classic "blood in the streets" moment. I'm calling it a speculative BUY for the brave. #ContrarianPlay

"FDA’s animal testing shift is *huge* for Simulations Plus—like giving them a golden ticket 🎟️. But hold up: RSI’s been flirting with overbought for weeks (yawn), and today’s drop on meh volume feels like profit-taking. Short-term? Maybe a pullback. Long-term? This stock’s got *legs*. Chart’s messy, but the news is too juicy to ignore. BUY the dip if you’re patient. #ScienceWinsButRSINaps"  

(Word count: 78. Boom.)

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.

Simulations Plus, Inc. SLP: 14.47 USD

Bullish views